Piper Sandler upgraded Alpha Tau Medical from Neutral to Overweight and set a $22 target, a favorable sign. The report adds no new trial or business results, so the positive case rests on the firm's opinion.
That change gives investors a more positive outside view of Alpha Tau. The story offers no new trial results or business figures, so it says more about Piper Sandler's opinion than a change in the company's progress.
Follow Alpha Tau Medical Ltd. (DRTS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DRTS